1.45Open1.15Pre Close30 Volume570 Open Interest15.00Strike Price5.43KTurnover94.89%IV5.03%PremiumSep 20, 2024Expiry Date0.89Intrinsic Value100Multiplier19DDays to Expiry0.71Extrinsic Value100Contract SizeAmericanOptions Type-0.5654Delta0.1294Gamma8.18Leverage Ratio-0.0308Theta-0.0045Rho-4.62Eff Leverage0.0127Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet